20 January 2026
: Case report 
Successful Long-Term Remission in Infantile Acute Leukemia Treated With Chemotherapy and Blinatumomab: A Case Report
Unusual or unexpected effect of treatment
Qiuying He E 1, Bin Zhang A 1, Shuang Li A 1, JiaWei Yang A 1, Liangchun Hao A 1*DOI: 10.12659/AJCR.950502
Am J Case Rep 2026; 27:e950502
Table 1 Therapeutic medications and complications.
| Treatment No. | Treatment | MRD | Complications | Treatment of Complications |
|---|---|---|---|---|
| Initial treatment (March 2023) | COLD + 28 days of blinatumomab | – | Fever; hypo-gammaglobulinemia; bone marrow suppression; abnormal liver function; abnormal coagulation | Gammaglobulin; meropenem; magnesium isoglucarate |
| 2 | HDMTX; 6-MP; VDS | Norovirus infection | ||
| 3 | High-dose cytarabine; pegaspargase | – | Pneumonia | Meropenem; micafungin; azithromycin; granulocyte colony-stimulating factor |
| 4 | VDAMD | – | Fever | Meropenem |
| 5 | COAD | – | ||
| 6 | CAM → Maintenance therapy | – | ||
| 7 | VCD + blinatumomab | Fever | Gammaglobulin; granulocyte colony-stimulating factor; meropenem; azithromycin | |
| 8 | HDMTX + VCLD | – | ||
| MRD – minimal residual disease; O/V - vindesine; C – cyclophosphamide; L – asparaginase; D – dexamethasone; HDMTX – high-dose methotrexate; A – cytarabine; M/6-MP – mercaptopurine. | ||||